MT2017-45: CAR-T Cell Therapy for Heme Malignancies

NCT03642626 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
Large B-cell Lymphoma

Interventions

DRUG: KYMRIAH
DRUG: YESCARTA
DRUG: Fludarabine 30mg/m2 4 doses
DRUG: Cyclophosphamide 500 mg/m2; 2 doses
DRUG: Fludarabine 30mg/m2 3 doses
DRUG: Cyclophosphamide 500 mg/m2; 3 doses
DRUG: Fludarabine 25mg/m2 3 days
DRUG: Cyclophosphamide 250 mg/m2; 3 days
DRUG: Tecartus
DRUG: Abecma, Intravenous Suspension
DRUG: Cyclophosphamide 900 mg/m2; 1 day
DRUG: Breyanzi Injectable Product

Sponsor

Masonic Cancer Center, University of Minnesota